- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04737174
ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors
March 28, 2022 updated by: ES Therapeutics Australia Pty Ltd
Adjunctive ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors
Phase 2A single-arm exploratory clinical study in up to 12 adult subjects aged 18 and older with primary glioma, IDH1 mutation, and uncontrolled focal-onset seizure activity to determine the potential efficacy, safety and pharmacokinetics of ES-481 as adjunctive therapy in glioma-associated epilepsy and to assess for potential anti-tumorigenic effects.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects greater than 18 years of age
- Subjects with brain tumour-related epilepsy
- Subjects with a history of uncontrolled seizures (at least three focal-onset seizure per month over the last 28 days)
- Subjects currently being treated with at least one appropriate AED
- Subjects who have had a brain MRI performed in the last three months preceding the signing of informed consent
- Subjects with primary brain tumour with an IDH1 mutation (to be determined during the screening period)
- Subjects with satisfactory hematologic, renal and liver function, as assessed by the Principal Investigator
- Subject with a Karnofsky performance scale index (KPD) of > 70%
- An expected survival time > 6 months
A female subject is eligible to participate if she is not pregnant by serum pregnancy test, not breastfeeding, and at least 1 of the following conditions applies:
- Not of childbearing potential, defined as surgically sterile (documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or postmenopausal (no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient)
- Of childbearing potential and agrees to use a highly effective method of contraception consistently during the 4-week dose escalation, 16-week treatment, and 4-week washout periods; and for at least 30 days after the last dose of study treatment
- A male patient with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception during 4-week dose escalation, 16-week treatment, and 4-week washout periods; and for at least 30 days after the last dose of study treatment and refrains from donating sperm during this period
- Willing to participate in the study and willing to provide written signed informed consent.
Exclusion Criteria:
- Urgent need for surgical intervention
- Alanine aminotransferase or aspartate aminotransferase > 10 times the upper reference limit at the screening visit
- Estimated glomerular filtration rate < 60 mL/min (calculated using the using the Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation) at the screening visit
- Any haematological National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 Grade ≥ 3 (with the exception of alopecia) at the screening visit
- Factors that significantly affect oral drug absorption, such as inability to swallow, chronic diarrhoea, short bowel syndrome, and/or intestinal obstruction
- Hypertension that cannot be reduced to normal range with antihypertensive medication (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg)
- Concurrent active cancer that requires non-surgical treatment (e.g., chemotherapy, radiotherapy, adjuvant therapy)
- History of severe cardiovascular disease: myocardial ischemia or myocardial infarction of Grade 2 or above, poorly controlled arrhythmia (including QTc interval ≥450 ms for men, ≥470 ms for women); according to New York Heart Association standards, Grade 3 or 4 cardiac insufficiency, or colour doppler ultrasound examination of the left ventricular ejection fraction < 50% as assessed at the screening visit
- In the Investigators opinion, the subject's involvement may affect the progress of the clinical study and/or the determination of the research results, and/or considers them unsuitable for inclusion
- Previously suffered severe cardiovascular disease: myocardial ischemia or myocardial infarction of Grade 2 or above, poorly controlled arrhythmia (including QTc interval ≥450 ms for men, ≥470 ms for women); according to New York Heart Association standards, Grade 3 or 4 cardiac insufficiency, or color doppler ultrasound examination of the left ventricular ejection fraction < 50%.
- Investigator judges that may affect the progress of the clinical study and/or the determination of the research results, and/or considers them unsuitable for inclusion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ES-481
Administered as 25 mg oral gelatin capsules
|
28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electroencephalogram Monitoring of epileptiform interictal and seizure discharge
Time Frame: Continual 24 hours
|
Continual 24 hours
|
|
Subject Captured Seizure Activity
Time Frame: Continual 24 hour
|
Subjects will keep daily diary of seizure activity
|
Continual 24 hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Terence O'Brien, MD, The Alfred Centre
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
March 25, 2021
Primary Completion (ANTICIPATED)
October 1, 2021
Study Completion (ANTICIPATED)
April 1, 2022
Study Registration Dates
First Submitted
January 26, 2021
First Submitted That Met QC Criteria
January 31, 2021
First Posted (ACTUAL)
February 3, 2021
Study Record Updates
Last Update Posted (ACTUAL)
April 6, 2022
Last Update Submitted That Met QC Criteria
March 28, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EST-481 2020-Onco-101-HGG
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy; Seizure
-
UMC UtrechtUnknownEpilepsy Intractable | Epileptic Seizure | Motor SeizureNetherlands
-
Michael A. Gelfand, MD, PhDEpilepsy FoundationCompletedGeneralized Tonic Clonic Seizure | Drug Resistant Epilepsy | Drop Seizures | Complex Partial Seizure | Fall Due to SeizureUnited States
-
Children's Hospital of Fudan UniversityRecruitingSeizures | Seizure Disorder | Seizure Newborn | Seizure GeneralizedChina
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedEpilepsy | Epilepsies, Partial | Partial Seizure Disorder | Complex Partial Seizure DisorderCosta Rica, Peru, El Salvador, Guatemala
-
Vitaflo International, LtdChildren's Hospital of PhiladelphiaCompletedSeizure DisordersUnited States
-
Dokuz Eylul UniversityRecruiting
-
University of California, San FranciscoCompleted
-
University of VirginiaUniversity of Wisconsin, Madison; Epilepsy FoundationCompletedEpilepsy; SeizureUnited States
-
Brain SentinelUnknownEpilepsy | Non-Epileptic Seizure | Motor SeizureAustria
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedEpilepsy | Seizures | Partial Seizure DisorderUnited States, Australia, France, Belgium, Taiwan, Spain, Argentina, Poland, India, Ukraine, Finland, Korea, Republic of, Russian Federation, Chile, Thailand, Hungary, Israel, New Zealand, Canada, Mexico, Norway, Netherlands, South...
Clinical Trials on ES-481
-
ES Therapeutics Australia Pty LtdRecruitingTremor, EssentialCanada
-
ES Therapeutics Australia Pty LtdRecruitingDrug Resistant EpilepsyAustralia
-
Swiss Paraplegic Centre NottwilCompletedOrthostatic Hypotension | Spinal Cord InjurySwitzerland
-
NICHD Pelvic Floor Disorders NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFecal Incontinence | Bowel IncontinenceUnited States
-
McGuire Research InstituteUnknown
-
Ottawa Heart Institute Research CorporationRecruitingCardiac DiseaseCanada
-
Tarbiat Modarres UniversityCompletedDiabetic FootIran, Islamic Republic of
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedCrohn's Disease | Ulcerative Colitis | Inflammatory Bowel Disease
-
Afyonkarahisar Health Sciences UniversityCompletedAnemia | Oxidative Stress
-
Chang Gung UniversityRecruiting